Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints NewsRO: Fenebrutinib matched ocrelizumab in slowing PPMS progression, with strong upper limb benefits TradingViewRO: Fenebrutinib demonstrated non-inferiority to OCREVUS in PPMS, reducing disability progression risk TradingView
